NTRK fusions and concomitant immune and genomic landscape detected by DNA and RNA comprehensive genomic profiling in a large healthcare system
Real-world data confirms that broader NTRK gene testing helps identify cancer patients eligible for newly available targeted drugs.
This real-world study from a large healthcare system uses dual DNA/RNA comprehensive genomic profiling to characterize NTRK fusions and their co-occurring immune and genomic landscape. The data support broader implementation of NTRK testing and inform patient selection for larotrectinib or entrectinib therapy.
What the study was
- Study design
- Retrospective observational study (large healthcare system)
- Population
- Cancer patients undergoing comprehensive genomic profiling in a large healthcare system
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Frontiers in Medicine
Why it surfaced
Large real-world NTRK genomic profiling study supports precision therapy selection; directly relevant to targeted therapy watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.